Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy

MT Newswires Live

2024/10/30

Tharimmune (THAR) shares climbed by more than 130% in recent Wednesday trading after the company said it received "positive feedback" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.

The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.

The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.

Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.

Price: 4.46, Change: +2.44, Percent Change: +120.79

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2479733406"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479733406\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2479733406?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479733406","market":"sh","top_or_hot":-1,"title":"Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy","media":"MT Newswires Live","content":"<html><body><p> Tharimmune (THAR) shares climbed by more than 130% in recent Wednesday trading after the company said it received \"positive feedback\" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.</p><p>The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.</p><p>The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.</p><p>Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.</p><p>Price: 4.46, Change: +2.44, Percent Change: +120.79</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-30 23:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tharimmune (THAR) shares climbed by more than 130% in recent Wednesday trading after the company said it received \"positive feedback\" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.</p><p>The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.</p><p>The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.</p><p>Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.</p><p>Price: 4.46, Change: +2.44, Percent Change: +120.79</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2479733406","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479733406","pubTimestamp":1730300791,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tharimmune  shares climbed by more than 130% in recent Wednesday trading after the company said it received \"positive feedback\" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.Price: 4.46, Change: +2.44, Percent Change: +120.79","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技"},"translate_title":"由于EMA对潜在瘙痒疗法的积极反馈，Tharimmune股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"THAR":0.9},"content_text":"Tharimmune (THAR) shares climbed by more than 130% in recent Wednesday trading after the company said it received \"positive feedback\" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.Price: 4.46, Change: +2.44, Percent Change: +120.79","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}